Antibodies by Design: Accelerating biotherapeutic R&D
We don't have the price yet; check it on thebiocalendar.com before you go.
See the listing on thebiocalendar.com ↗About
Scala Biodesign’s co-founders Ravit Netzer and Adi Goldenzweig discuss the science and experimental evidence behind its antibody design technology. They explain how AI and physics-based calculations are used to improve multiple antibody properties and present experimental case studies and the challenges each project set out to solve.
From the organizer
Join us on November 4th to discuss the science and experimental evidence behind Scala Biodesign\'s antibody design technology. Scala’s co-founders Ravit Netzer and Adi Goldenzweig will explain how we combine AI and physics-based calculations to improve multiple antibody properties. They’ll walk through experimental case studies, the challenges each project set out to solve, and what...
\n
Also that day
Fact check
Conflicting details- Date: not confirmed
- Time: not confirmed
- Venue: confirmed
- Open to public: confirmed
Conflicting details. Sources disagree about whether it is in person or online.
Checked 17h ago against biospace.com · Source: thebiocalendar.com